{"classes":[{"categories":[{"measurements":[{"comment":"Data for upper limit of CI is not available due to low number of participants with events.","groupId":"OG000","lowerLimit":"4.7","upperLimit":"NA","value":"57.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"DOR: time from the first OR to PD/death. It is determined using KM estimates. PD: score 4 (uptake moderately \\> liver)/5 (uptake markedly \\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim/EOT assessment; new FDG-avid foci consistent with lymphoma rather than another etiology; new/recurrent FDG-avid foci in bone marrow; an individual node/lesion must be abnormal with: LDi \\> 1.5 cm, increase by ≥ 50% from cross-product of LDi and PPD nadir, increase in LDi or shortest axis perpendicular to the LDi from nadir, the splenic length must increase by \\> 50% of the extent of its prior increase beyond baseline. If no prior splenomegaly, the increase must be ≥ 2 cm from baseline; new/recurrent splenomegaly; new or clear progression of pre-existing NMLs; new lesion; new/recurrent bone marrow involvement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants from the mITT analysis Set with objective response in Cohort 2 were analyzed. Participants not meeting the criteria for DOR at the time of data analysis were censored at their last evaluable disease assessment date.","reportingStatus":"POSTED","timeFrame":"Up to 7.8 years","title":"Duration of Response (DOR) in Cohort 2 as Per Investigator Response","type":"SECONDARY","unitOfMeasure":"months"}